Research letterTumor necrosis factor-α inhibitors for the treatment of pyoderma gangrenosum not associated with inflammatory bowel diseases: A multicenter retrospective study
References (4)
- et al.
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease
Am J Gastroenterol
(2003) - et al.
A comprehensive review of neutrophilic diseases
Clin Rev Allergy Immunol
(2018)
There are more references available in the full text version of this article.
Cited by (13)
Treatment Strategies in Neutrophilic Dermatoses: A Comprehensive Review
2023, International Journal of Molecular SciencesCutaneous Manifestations of Rheumatoid Arthritis: Diagnosis and Treatment
2023, Journal of Personalized MedicineInformed consent and biological agents in rheumatology and internal medicine
2022, European Journal of Clinical Investigation
Funding sources: None.
Conflicts of interest: None disclosed.
Reprints not available from the authors.
© 2018 by the American Academy of Dermatology, Inc.